One To Watch

ADARx Pharmaceuticals

A late clinical-stage RNA therapeutics company developing siRNA medicines across complement-mediated disease, cardiovascular and thrombosis, and selected metabolic and CNS indications. Its most advanced disclosed programs target complement factor B, plasma prekallikrein, angiotensinogen and factor XI.

Headquarters and Global Presence

ADARx is headquartered in San Diego, California. The company runs clinical development through multicenter trial networks in the US and other trial geographies depending on indication.

Founding and History

ADARx was founded in 2019 and has built a portfolio of siRNA programs intended to deliver durable target knockdown with periodic dosing. In May 2025, the company entered a collaboration and license option agreement with AbbVie to develop siRNA therapeutics across multiple disease areas.

Therapy Areas and Focus

ADARx’ disclosed R&D priorities span:

Complement-mediated diseases: renal disease, ophthalmology and hematology settings where alternative pathway biology is implicated
Cardiovascular and cardiometabolic disease: hypertension and metabolic programs
Thrombosis: factor XI silencing for prevention of thrombotic events with reduced bleeding risk relative to conventional anticoagulation approaches
Rare disease: hereditary angioedema
CNS and neurodegeneration: programs disclosed as early-stage or undisclosed

Technology Platforms and Modalities

ADARx develops small interfering RNA medicines designed for potent, durable and selective gene silencing, supported by proprietary delivery approaches.

Disclosed clinical-stage programs include:

ADX-038, complement factor B: Phase I completed/ongoing readouts and Phase II development across three indications
IgA nephropathy and complement-mediated renal disease (including C3G): Phase II
Geographic atrophy: Phase II
Paroxysmal nocturnal hemoglobinuria: Phase II
ADX-324, plasma prekallikrein: Phase III planned/initiating for hereditary angioedema
ADX-850, angiotensinogen: Phase I b in hypertension, positioned to suppress hepatic AGT while sparing kidney AGT production
ADX-626, factor XI: Phase I in healthy participants for thrombotic disease settings

Earlier programs listed by the company include ADX-077 (obesity/metabolic), ADX-199 (neurodegeneration), and additional undisclosed CNS, immunology and oncology programs.

Key Personnel

Zhen Li, PhD: Co-founder, President and Chief Executive Officer
Donald Fong, MD: Chief Medical Officer (appointed February 2026)
Ajim Tamboli, CFA: Chief Financial Officer (appointed July 2024)
Robert A. MacLeod, PhD: Chief Scientific Officer
Rui Zhu, PhD: Chief Technology Officer
Christopher Claeboe, PhD, MBA: Senior Vice President of Operations

Strategic Partnerships
ADARx’ most prominent disclosed partnership is its AbbVie collaboration (May 2025), structured as a collaboration and license option framework to develop next-generation siRNA therapies across neuroscience, immunology and oncology, alongside ADARx’ wholly owned clinical pipeline.

FAQ Section

ADARx develops siRNA medicines intended to silence disease-driving genes with durable knockdown, enabling infrequent dosing strategies in chronic disease.

The company’s disclosed focus includes complement-mediated disease (renal, ophthalmic and hematologic), hereditary angioedema, hypertension, thrombotic diseases, and selected metabolic and CNS programs.

Disclosed clinical-stage assets include ADX-038 (CFB) in Phase II across IgA nephropathy/C3G, geographic atrophy and PNH; ADX-324 (PKK) in Phase III development for hereditary angioedema; ADX-850 (AGT) in Phase I b for hypertension; and ADX-626 (factor XI) in Phase I for thrombotic disease settings.

Recent disclosed updates include the February 5, 2026 appointment of Donald Fong as Chief Medical Officer, and the November 7, 2025 report of positive interim Phase I data for ADX-038 highlighting near-complete alternative pathway suppression for up to six months after a single dose, supporting ongoing Phase II studies.

ADARx has publicly emphasized Phase I pharmacology showing durable complement alternative pathway suppression consistent with CFB silencing, which it is using to support Phase II studies in complement-mediated renal disease, geographic atrophy and PNH.

Key milestones are Phase II progress and readouts across the ADX-038 indications, initiation and execution of the Phase III program for ADX-324 in hereditary angioedema, continued Phase I b development for ADX-850 in hypertension, and Phase I progress for ADX-626.

Differentiation is program-specific, but the company’s positioning centers on durable target knockdown and selective biology choices (for example, complement factor B for alternative pathway suppression; factor XI for thrombosis with reduced bleeding risk) combined with delivery strategies intended to support convenient dosing intervals.

Want to Update your Company's Profile?